Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells

Journal of Immunology

Volumn 161, Issue 12, 1998, Pages 6977-6984

  Chapoval, Andrei I ^a,b   Fuller, Jane A ^b   Kremlev, Sergey G ^b   Kamdar, Sonya J ^b   Evans, Robert ^b  

^a MAYO CLINIC   (United States)

^b JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; INTERLEUKIN 15;

ADJUVANT CHEMOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER SURVIVAL; CELL MATURATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; EFFECTOR CELL; IMMUNE RESPONSE; LUNG METASTASIS; LUNG TUMOR; LYMPHOKINE ACTIVATED KILLER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOSARCOMA; TUMOR MODEL; TUMOR REGRESSION;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS, ALKYLATING; B-LYMPHOCYTES; BIOLOGICAL RESPONSE MODIFIERS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTOTOXICITY, IMMUNOLOGIC; DRUG SCREENING ASSAYS, ANTITUMOR; H-2 ANTIGENS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC MEMORY; INTERLEUKIN-15; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RHABDOMYOSARCOMA; T-LYMPHOCYTE SUBSETS;

EID: 0032534579     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Grabstein, K. H., J. Eisenman, K. Shanebeck, C. Rauch, S. Srinivasan, V. Fung, C. Beers, J. Richardson, M. A. Schoenborn, and M. Ahdieh. 1994. Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor. Science 264:965.
2. McInnes, I. B., B. P. Leung, R. D. Sturrock, M. Field, and F. Y. Liew. 1997. Interleukin-15 mediates T cell-dependenl regulation of tumor necrosis factor-α production in rheumatoid arthritis. Nat. Med. 3:189.
3. Carson, W. E., J. G. Giri, M. J. Lindemann, M. L. Linett, M. Ahdieh, R. Paxton, D. Anderson, J. Eisenmann, K. Grabstein, and M. A. Caligiuri. 1994. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180:1395.
4. Giri, J. G., M. Ahdieh, J. Eisenman, K. Shanebeck, K. Grabstein, S. Kumaki, A. Namen, L. S. Park, D. Cosman, and D. Anderson. 1994. Utilization of the β and γ chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 13:2822.
5. Nishimura, H., K. Hiromatsu, N. Kobayashi, K. H. Grabstein, R. Paxton, K. Sugamura, J. A. Bluestone, and Y. Yoshikai. 1996. IL-15 is a novel growth factor for murine γδ T cells induced by Salmonella infection. J. Immunol. 156: 663.
6. Armitage, R. J., B. M. Macduff, J. Eisenman, R. Paxton, and K. H. Grabstein. 1995. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J. Immunol 154:483.
7. Alleva, D. G., S. B. Kaser, M. A. Monroy, M. J. Fenton, and D. I. Beller. 1997. IL-15 functions as a potent autocrine regulator of macrophage proinflammatory cytokine production: evidence for differential receptor subunit utilization associated with stimulation or inhibition. J. Immunol. 159:2941.
8. Girard, D., M. E. Paquet, R. Paquin, and A. D. Beaulieu. 1996. Differential effects of interleukin-15 (IL-15) and IL-2 on human neutrophils: modulation of phagocytosis, cytoskeleton rearrangement, gene expression, and apoptosis by IL-15, Blood 88:3176.
9. Ye, W., J. D. Young, and C. C. Liu. 1996. Interleukin-15 induces the expression of raRNAs of cytolytic mediators and augments cytotoxic activities in primary murine lymphocytes. Cell. Immunol. 174:54.
10. Gamero, A. M., D. Ussery, D. S. Reintgen, C. A. Puleo, and J. Y. Djeu. 1995. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. Cancer Res. 55:4988.
11. Takeuchi, E., H. Yanagawa, S. Yano, T. Haku, and S. Sone. 1996. Induction by interleukin-15 of human killer cell activity against lung cancer cell lines and its regulatory mechanisms. Jpn. J. Cancer Res. 87:1251.
12. Lewko, W. M., T. L. Smith, D. J. Bowman, R. W. Good, and R. K. Oldham. 1995. Interleukin-15 and the growth of tumor derived activated T-cells. Cancer Biother. 10:13.
13. Mingari, M. C., C. Vitale, C. Cantoni, R. Bellomo, M. Ponte, F. Schiavetti, S. Bertone, A. Moretta, and L. Moretta. 1997. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor. Eur. J. Immunol. 27:1374.
14. Yoshimoto, T., K. Nakanishi, S. Hirose, K. Hiroishi, H. Okamura, Y. Takemoto, A. Kanamaru, T. Hada, T. Tamura, and E. Kakishita. 1992. High serum IL-6 level reflects susceptible status of the host to endotoxin and IL-I/tumor necrosis factor. J. Immunol. 148:3596.
15. Munger, W., S. Q. DeJoy, R. Jeyaseelan, Sr., L. W. Torley, K. H. Grabstein, J. Eisenmann, R. Paxton, T. Cox, M. M. Wick, and S. S. Kerwar. 1995. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell. Immunol. 165:289.
16. Evans, R., J. A. Fuller, G. Christianson, D. M. Krupke, and A. B. Troutt. 1997. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations. Cell. Immunol. 179:66.
17. 1-2+ effector T cells. J. Exp. Med. 159:1295.
18. Rothe, H., A. Faust, U. Schade, R. Kleemann, G. Bosse, T. Hibino, S. Martin, and H. Kolb. 1994. Cyclophosphamide treatment of female non-obese diabetic mice causes enhanced expression of inducible nitric oxide synthase and interferon-γ, but not of interleukin-4. Diabetologia 37:1154.
19. 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: augmentation with cyclophosphamide and correlation with response. Cancer 73:1731.
20. Schoof, D. D., A. F. Massaro, J. A. Obando, J. C. Kusack, Jr., and T. J. Eberlein. 1992. The biological effects of immunosuppression on cellular immunotherapy. Surg. Oncol. 1:27.
21. Kedar, E., R. Ben-Aziz, E. Epstein, and B. Leshem. 1989. Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide: IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type. Cancer Immunol. Immunother. 29:74.
22. Evans, R., L. D. Madison, and D. M. Eidlen. 1980. Cyclophosphamide-induced changes in the cellular composition of a methylcholanthrene-induced tumor and their relation to bone marrow and blood leukocyte levels. Cancer Res. 40:395.
23. + large granular lymphocyte precursors after cyclophosphamide injection: in vitro characterization and potential therapeutic application. Nat. Immun. 13:246.
24. Evans, R., S. J. Kamdar, T. Duffy, and L. Edison. 1993. Intratumor gene expression after adoptive immunotherapy in a murine tumor model: regulation of messenger RNA levels associated with the differential expansion of tumor-infiltrating lymphocytes. J. Immunol. 150:177.
25. Evans, R. 1980. Further observations on the effect of cyclophosphamide on intratumor and peripheral leukocyte levels. Am. J. Pathol. 99:667.
26. Chapoval, A. I., S. J. Kamdar, S. G. Kremlev, and R. Evans. 1998. CSF-1 (M-CSF) differentially sensitizes mononuclear phagocyte subpopulations to endotoxin in vivo: a potential pathway that regulates the severity of Gram-negative infections. J. Leukocyte Biol. 63:245.
27. Wexler, H. 1966. Accurate identification of experimental pulmonary metastases. J. Natl. Cancer Inst. 36:641.
28. Evans, R., and T. M. Duffy. 1989. Adoptive immunotherapy is suppressed in C57BL/6J and B6.C-H-2bml2 mice following recognition of congenic class II MHC antigen determinants. Inc. J. Cancer 44:854.
29. Proietti, E., G. Greco, B. Garrone, S. Baccarini, C. Mauri, M. Venditti, D. Carlei, and F. Belardelli. 1998. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J. Clin. Invest. 101:429.
30. Evans, R., S. J. Kamdar, and T. M. Duffy. 1994. Qualitative and quantitative intratumoral changes in gene expression following cyclophosphamide injection and the adoptive transfer of T cells: the potential contribution of tumor-associated macrophages. Int. J. Cancer 56:568.
31. Korholz, D., U. Banning, H. Bonig, M. Grewe, M. Schneider, C. Mauz-Korholz, A. Klein-Vehne, J. Krutmann, and S. Burdach. 1997. The role of interleukin-10 (IL-10) in IL-15-mediated T-cell responses. Blood 90:4513.
32. Carson, W. E., M. E. Ross, R. A. Baiocchi, M. J. Marien, N. Boiani, K. Grabstein, and M. A. Caligiuri. 1995. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-γ by natural killer cells in vitro. J. Clin. Invest. 96:2578.
33. Sprent, J. 1997. Immunological memory. Curr. Opin. Immunol. 9:371.
34. Saxena, R. K., Q. B. Saxena, and W. H. Adler. 1982. Defective T-cell response in beige mutant mice. Nature 295:240.
35. Germain, R. N., and D. H. Margulies. 1993. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 11:403.
36. Ensslin, A. S., and B. Formby. 1991. Comparison of cytolytic and proliferative activities of human γδ and αβ T cells from peripheral blood against various human tumor cell lines. J. Natl. Cancer Inst. 83:1564.
37. Ericsson, P. O., J. Hansson, B. Widegren, M. Dohlsten, H. O. Sjogren, and G. Hedlund. 1991. In vivo induction of γ/δ T cells with highly potent and selective anti-tumor cytotoxicity. Eur. J. Immunol. 21:2797.
38. Cheng, S. H., J. M. Penninger, D. A. Ferrick, T. J. Molina, V. A. Wallace, and T. W. Mak. 1991. Biology of murine γδ T cells. Crit. Rev. Immunol 11:145.
39. Kanegane, H., and G. Tosato. 1996. Activation of naive and memory T cells by interleukin-15. Blood 88:230.
40. c-chains of the IL-2 receptor. J. Invest. Dermatol. 105:837.
41. Qin, Z., and T. Blankenstein. 1995. Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response. Cancer Res. 55:4747.
42. Miller, K., G. Abeles, R. Oratz, A. Zeleniuch-Jacquotte, J. Cui, D. F. Roses, M. N. Harris, and J. C. Bystryn. 1995. Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 75:495.
43. Gordon, J., H. T. Holden, S. Segal, and M. Feldman. 1982. Anti-tumor immunity in B-lymphocyte-deprived mice. III. Immunity to primary Moloney sarcoma virus-induced tumors. Int. J. Cancer 29:351.
44. Brodt, P., and J. Gordon. 1978. Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. J. Immunol. 121:359.
45. + and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells. Transplantation 55:1356.
46. Hellstrom, K. E., and I. Hellstrom. 1972. Immunity to neuroblastomas and melanomas. Annu. Rev. Med. 23:19.
47. Levy, J. G., R. McMaster, B. Kelly, R. B. Whitney, and D. G. Kilburn. 1977. Identity of a T-lymphocyte inhibitor with mouse immunoglobulin in the serum of tumor-bearing mice. Immunology 32:475.
48. + T cell subsets to Plasmodium chabaudi chabaudi in B cell-deficient mice. Int. Immunol 5:1343.
49. Taylor-Robinson, A. W., and R. S. Phillips. 1996. Reconstitution of B-cell-depleted mice with B cells restores Th2-type immune responses during Plasmodium chabaudi chabaudi infection. Infect. Immun. 64:366.
50. Salvucci, O., F. Mami-Chouaib, J. L. Moreau, J. Theze, J. Chehimi, and S. Chouaib. 1996. Differential regulation of interleukin-12-and interleukin-15-induced natural killer cell activation by interleukin-4. Eur. J. Immunol. 26:2736.